Mars Finance News, May 25 — DeShi Bio (02526.HK) recently announced that its independently developed AI AutoVision® Chromosome Karyotype Assistive Diagnostic Software has officially received the Class III Medical Device Registration Certificate from the National Medical Products Administration. It is understood that AI AutoVision® relies on the iMedImage® foundational model and proprietary AI algorithms to achieve one-click chromosome recognition, segmentation, counting, arrangement, and case-level abnormality detection. It can intelligently alert for abnormalities such as triploidy, monosomy, translocation, inversion, and deletion, upgrading the analysis process from "manual interpretation" to "AI automatic analysis + doctor review." According to the official website, DeShi leverages its independently developed general medical imaging foundational model iMedImage® to create a diversified matrix of intelligent equipment and supporting products, including the AI AutoVision® Chromosome Karyotype Assistive Diagnostic System, MetaSight® Automatic Cell Microscopic Image Scanning System, KayoFlow® Automatic Cell Harvesting and Slide Preparation Integrated Machine, among others.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

10 Likes

Reward
10
11
1
Share

Comment

Add a comment

LongHandHODL

· 05-26 18:51

The positioning of auxiliary diagnosis is very clever, it doesn't compete with doctors for their jobs, but serves as an efficiency tool.

View OriginalReply0

NonceWhisperer

· 05-26 14:24

Getting the certificate is just the beginning; the real challenge is later integrating into medical insurance and hospital procurement lists.

View OriginalReply0

PoolDiver

· 05-25 12:13

From software to device matrix, Deshi is playing this game quite big.

View OriginalReply0

HashPeak

· 05-25 11:25

The name MetaSight sounds quite sci-fi; the device matrix is gradually being deployed.

View OriginalReply0

FinanceMartingale

· 05-25 11:17

Translocation and deletion hints need to be sufficiently accurate; their value in prenatal diagnosis scenarios is significant.

View OriginalReply0

MemeFisher

· 05-25 11:14

Clinical implementation is the real key; looking forward to actual feedback from the hospital side.

View OriginalReply0

TwoFactorZen

· 05-25 11:07

One-click to handle splitting, counting, and arranging; the lab colleagues probably won't have to stay up late as much.

View OriginalReply0

LunaCircuit

· 05-25 11:07

Is the iMedImage base developed in-house? Autonomous control of underlying technology is becoming increasingly important.

View OriginalReply0

SlippageSiren

· 05-25 11:07

Chromosome abnormality detection was previously done entirely by manual inspection, but now there is finally an assistant.

View OriginalReply0

TheWindOnTheBridgeIsTooStrong.

· 05-25 11:07

AI + doctor review double insurance model, improving efficiency without losing professionalism

View OriginalReply0

Trending Topics
View More
#
USD1StakingEarnUpTo8%APR
690.32K Popularity
#
GateCardUpTo8%Cashback
27.07K Popularity
#
SKHynixEarningsMissTriggerPostMarketDrop
892.98K Popularity
#
NFTSectorSurgesOver8%
14.33M Popularity
#
SECChairOptimisticOnCLARITYAct
2.27M Popularity

Pinned

Sitemap

Deshisheng Biology: Chromosome Karyotype Auxiliary Imaging Diagnostic Software Approved for Market Release

Trending Topics

USD1StakingEarnUpTo8%APR

GateCardUpTo8%Cashback

SKHynixEarningsMissTriggerPostMarketDrop

NFTSectorSurgesOver8%

SECChairOptimisticOnCLARITYAct

Pinned